Key Takeaways
- Direct-to-consumer telehealth platforms are prescribing off-label ketamine with liability and ethical frameworks that have not kept pace with the scale of that practice, according to a 2025 analysis in Psychiatric Services.
- State-level rules on peptide availability in sexual medicine vary so widely that patients in some states can obtain unapproved compounds with no meaningful clinical gatekeeping, per a 2025 study in Sexual Medicine.
- A global scoping review in the Journal of Telemedicine and Telecare found that telemedicine-enabled buprenorphine prescribing faces inconsistent regulatory barriers across countries, leaving opioid use disorder patients with uneven access.
- The American College of Physicians’ 2025 position paper in Annals of Internal Medicine calls for federal standards on telehealth prescribing that currently do not exist.
- Community pharmacists in Indonesia are operating telepharmacy services without any regulatory support, a gap documented in the Journal of Epidemiology and Global Health that mirrors unresolved oversight problems in higher-income countries.
How fast is telehealth drug access growing, and who is watching it?
Telehealth drug access is growing fast — and the oversight systems meant to watch it are struggling to keep pace. Across the United States, patients can now receive prescriptions for controlled substances, compounded peptides, off-label ketamine, and HIV-prevention medications through platforms that operate entirely online, often without a prior in-person exam.
The numbers tell a clear story. Research tracking telemedicine-enabled prescribing of medications for opioid use disorder found that telehealth buprenorphine access expanded significantly across multiple countries, yet regulatory frameworks governing those prescriptions vary so widely that patients in different jurisdictions face completely different standards of care from the same type of platform — a gap documented in a global review of telemedicine MOUD practices. PrEP (pre-exposure prophylaxis for HIV prevention) shows a similar pattern: a federally funded surveillance protocol launched specifically to track how telehealth delivery is changing PrEP uptake acknowledges that existing data systems were not built to capture this kind of prescribing at scale, leaving researchers working backward to reconstruct trends from incomplete records, per the PREMISE study protocol.
Who is watching? Several agencies. None comprehensively.
The DEA sets federal rules on controlled-substance prescribing via telehealth, but enforcement against individual platforms is reactive, not proactive. State medical boards license prescribers, but a telehealth company operating across 30 states answers to 30 different boards with 30 different standards — a structural problem the American College of Physicians position paper on telemedicine policy (source) identifies as a core barrier to consistent patient protection. The FDA regulates drugs, not prescribing practices, which means a compounded peptide sold through a telehealth platform can reach patients in states with minimal prescribing guardrails — a dynamic documented in research on state-level peptide availability in sexual medicine. Liability for off-label prescribing through direct-to-consumer platforms sits in genuinely contested legal territory. A 2025 analysis of ketamine telehealth found that neither existing malpractice frameworks nor platform terms of service clearly assign responsibility when harm occurs, leaving patients with limited recourse — per the ketamine telehealth liability review.
Patients navigating this landscape should know that “telehealth-approved” is a marketing phrase, not a regulatory status. No single federal body pre-approves telehealth prescribing platforms before they go live.
This section presents general information drawn from published research and public records. It is not medical advice, and nothing here should substitute for a conversation with a licensed healthcare provider about your specific situation.
What does the research say about off-label ketamine sold through telehealth apps?
Disclaimer: This section contains general health information only and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional before making any decisions about your care.
Research on off-label ketamine sold through telehealth is sparse, contested, and trailing far behind the commercial market. A 2025 analysis in JAMA Network Open found that the telehealth ketamine industry has expanded dramatically faster than the clinical evidence base, creating a gap PMID 42159594 describes as a serious liability and ethical problem for both prescribers and patients.
What the evidence actually shows:
The FDA approved esketamine (Spravato) as a nasal spray for treatment-resistant depression in 2019, but only under a restricted program requiring in-clinic administration and monitoring. Oral ketamine lozenges—the product most telehealth apps sell—carry no FDA approval for any psychiatric indication. Prescribers writing those orders work entirely off-label, which is legal but shifts the burden of justifying safety and efficacy onto the individual clinician.
Most clinical trials supporting ketamine’s antidepressant effects used IV infusion in controlled settings, with doses and blood levels that differ substantially from oral lozenge formulations. PMID 42159594 notes that direct-to-consumer telehealth models skip the monitoring infrastructure those trials relied on, making it difficult to apply trial results to what patients actually receive at home.
When adverse events occur outside a clinical setting, the prescribing clinician faces significant legal exposure, and patients may have limited recourse if the telehealth company is structured to minimize liability. Thin intake assessments, no in-person evaluation, and no required follow-up are documented patterns in the direct-to-consumer ketamine market.
The American College of Physicians called for telemedicine prescribing to meet the same standard of care as in-person prescribing in a 2025 position paper—a standard PMID 42114091 argues many current telehealth controlled-substance models do not meet.
Dissociation, cardiovascular stress, and psychological distress are documented risks of ketamine use even in clinical settings. At home, alone, with no monitoring, those risks do not disappear because a company’s website uses the word “guided.” Patients asking their telehealth provider what evidence supports their specific formulation, dose, and delivery method deserve a direct answer—and should be skeptical if they don’t get one.
Are unapproved peptides reaching patients through online sexual medicine platforms?
Yes, unapproved peptides are reaching patients through online sexual medicine platforms, and the telehealth drug access pathway is the primary route making that possible at scale. A 2025 study in Sexual Medicine found that state-level regulatory variation directly shapes which peptides patients can obtain through telehealth-connected prescribers and compounding pharmacies — meaning a patient in one state may receive PT-141 (bremelanotide) or kisspeptin analogs through a telehealth visit while a patient two states over cannot, not because the drugs are approved in one jurisdiction and not the other, but because enforcement intensity differs.
The FDA has not approved most peptides marketed through sexual medicine telehealth platforms for the conditions being treated. PT-141 has FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women, but the compounded versions sold through many telehealth platforms are not that drug — they are bulk-manufactured peptides that bypass the approval process entirely. The Sexual Medicine study documents that availability of these compounds correlates with state prescribing rules and compounding pharmacy oversight gaps, not with any federal safety determination.
Patients encounter these products through a predictable funnel. A telehealth platform markets “sexual wellness” or “performance optimization” services. An affiliated prescriber — sometimes in a different state than the patient — writes a prescription after a brief asynchronous questionnaire. A compounding pharmacy ships the peptide directly to the patient’s door, often with minimal follow-up.
The American College of Physicians warned that telehealth prescribing models can outpace the clinical safeguards that in-person care provides, including physical examination and longitudinal monitoring, and called for clearer federal standards governing what can be prescribed through digital-only encounters — a gap that sexual medicine platforms are currently filling on their own terms, according to the ACP position paper.
The liability picture is murky for patients. Research on off-label telehealth prescribing found that when a drug causes harm outside its approved indication, patients face significant difficulty establishing who bears responsibility — the platform, the prescriber, or the pharmacy — because telehealth business structures deliberately separate those roles, as research on direct-to-consumer ketamine telehealth documents in a closely parallel context.
Patients should ask any sexual medicine telehealth provider three direct questions before accepting a prescription: Is this compound FDA-approved for my specific condition? Is the pharmacy dispensing it an FDA-registered facility? And what monitoring plan exists if I experience side effects?
This section contains general health information only and is not medical advice, diagnosis, or a treatment recommendation. Consult a licensed healthcare professional before starting, stopping, or changing any medication or supplement.
How are telemedicine rules affecting buprenorphine access for opioid use disorder?
Disclaimer: This section contains general health policy information only and is not medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare provider about your individual situation.
Telemedicine rules are directly shaping telehealth drug access for buprenorphine. Right now, patients face a regulatory landscape that is both more open than it was five years ago and more uncertain than providers are letting on. A temporary federal waiver allowed telehealth prescribing of buprenorphine without an in-person visit. That waiver is set to expire, and what replaces it will determine whether millions of people can keep their prescriptions.
The evidence is clear. A 2025 global review published in Drug and Alcohol Dependence found that telemedicine-delivered medications for opioid use disorder — buprenorphine chief among them — reached patients in rural and underserved areas who had no realistic alternative. Clinicians and program administrators across multiple countries named regulatory instability across jurisdictions as the single most-cited barrier to their practice. That comes from the people doing the work, not from telehealth marketing.
Patient outcomes matter. A retrospective cohort study found that patients receiving buprenorphine for opioid use disorder showed measurable reductions in emergency department visits and hospitalizations compared to baseline. Losing telehealth access to buprenorphine is not an abstract policy question. It has concrete health consequences.
The American College of Physicians, in a 2025 position paper, called on policymakers to make telehealth prescribing flexibilities permanent for conditions where evidence supports remote care, and specifically named opioid use disorder as a priority area. The ACP warned that inconsistent state-level rules create gaps where patients fall through — a provider licensed in one state cannot prescribe across state lines without meeting that second state’s requirements.
What patients navigating this system should watch for:
- Telehealth platforms advertising “easy buprenorphine prescriptions” without disclosing their state-by-state coverage limits are leaving patients exposed to sudden care interruptions if the regulatory ground shifts.
- The DEA’s proposed rules on telemedicine prescribing of controlled substances have gone through multiple comment periods and revisions. No permanent rule was finalized as of mid-2025, meaning the legal basis for your prescription may rest on temporary extensions.
- If a telehealth provider cannot tell you exactly which DEA and state rules cover your prescription, that is a red flag worth pressing on before you start treatment.
The same pattern that researchers identified in off-label ketamine telehealth — where direct-to-consumer platforms outpaced regulatory clarity and left patients holding liability risk — is a live concern for buprenorphine telehealth too. Ask your provider what happens to your prescription if the waiver expires. Get the answer in writing.
What happens when telepharmacy operates with no regulatory framework at all?
When telepharmacy runs without a regulatory framework, telehealth drug access becomes a system where pharmacists make up the rules as they go — and patients absorb the risk. A 2025 study in Indonesia found exactly that: community pharmacists operating telepharmacy services with no regulatory support reported improvising their own protocols, with no standardized verification process, no consistent documentation requirements, and no clear accountability when something went wrong.
The Indonesia findings name concrete mechanisms of failure, not just abstract concerns:
Pharmacists could not verify patient identity or confirm prescriptions through any official channel, so they relied on personal judgment — which varied widely from one pharmacy to the next. Without documentation standards, there was no reliable record of what was dispensed, to whom, or on what clinical basis. A patient harmed by a drug interaction had no paper trail to support a complaint. Pharmacists reported feeling legally exposed but had no guidance on how to protect themselves or their patients, so many simply avoided the most complex cases — meaning the patients with the greatest need got the least help.
Regulatory gaps don’t just create risk; they create avoidance. Pharmacists in the study pulled back from high-stakes consultations precisely because no framework told them what “safe practice” looked like.
The American College of Physicians made a parallel argument in its 2024 position paper on telemedicine: ACP’s position states that telehealth services require clear policy structures covering prescribing authority, documentation, and cross-jurisdictional practice — and that the absence of those structures leaves both patients and clinicians in an unworkable position.
Direct-to-consumer telehealth compounds this. Research on off-label ketamine prescribing through telehealth platforms found that when clinical and legal guardrails are absent, liability and ethical exposure fall on individual providers who may lack the institutional support to manage them — and patients may receive controlled substances with no meaningful follow-up care built into the model.
No framework means no floor. Patients using telepharmacy services in unregulated environments have no guaranteed minimum standard of care, no clear path to recourse, and no way to know whether the pharmacist on the other end of the screen is following any protocol at all.
This section presents general information for educational purposes and is not medical advice. Consult a qualified healthcare professional for guidance specific to your situation.
What policy changes do researchers and medical societies say are needed now?
Researchers and medical societies say telehealth drug access needs a unified federal framework — not the current patchwork of state rules and pandemic-era waivers that expire, get extended, and expire again. The American College of Physicians made this explicit in its 2025 position paper, calling on Congress and federal agencies to make permanent the telehealth prescribing flexibilities that have let patients receive care without mandatory in-person visits.
The American College of Physicians demands several specific changes:
- Permanent authorization for interstate telehealth prescribing, so a patient in a rural state can see a licensed provider in another state without either party risking a legal violation.
- Standardized documentation requirements across specialties, so providers know exactly what records they must keep and patients can verify that their care meets a consistent standard.
- Payer parity rules that require insurers to reimburse telehealth visits at the same rate as in-person visits for equivalent services.
On controlled substances, the stakes are higher. Researchers studying off-label ketamine prescribed through direct-to-consumer telehealth platforms found that existing liability rules are poorly matched to the business models these companies use. Patients who experience harm may have limited legal recourse. The ketamine telehealth liability study called on the DEA and state medical boards to clarify prescriber responsibility when a platform, not a traditional practice, sits between the patient and the clinician.
Opioid treatment is another pressure point. A global review of telemedicine-enabled buprenorphine programs found that countries with clear national policies saw better patient retention than those relying on temporary emergency rules. The researchers recommended that the U.S. codify audio-only prescribing as a permanent option, because patients in areas with poor broadband cannot reliably complete video visits.
Documentation gaps cut across all of these issues. A global scoping review on telemedicine documentation in neurology found wide variation in what providers record, making it nearly impossible for regulators or patients to audit whether care met any standard at all. The authors called for specialty-specific documentation templates with minimum required fields — a change that would also give patients a clearer record of what they were prescribed and why.
State-level inconsistency compounds every problem above. A study on peptide availability in sexual medicine found that which drugs a patient can access through telehealth depends heavily on their zip code, with no clinical rationale for the differences. Researchers recommended that federal agencies set a baseline access floor so geography stops functioning as a de facto formulary.
This section presents general information drawn from published research and policy documents. It is not medical advice. Consult a qualified healthcare professional about your specific situation.
FAQ
What is telehealth drug access and why is it under scrutiny?
Telehealth drug access refers to obtaining prescription or compounded medications through virtual care platforms rather than in-person clinical visits. Regulators and researchers are scrutinizing it because prescribing standards, liability rules, and pharmacy oversight have not kept pace with the rapid growth of direct-to-consumer telehealth services.
Is it legal to prescribe ketamine through a direct-to-consumer telehealth app?
Off-label ketamine prescribing through telehealth is not uniformly prohibited, but a 2025 analysis in Psychiatric Services found that liability risks and ethical responsibilities for clinicians doing so are poorly defined. The authors identified gaps in informed consent practices and post-prescribing monitoring that current regulations do not require platforms to close.
Can patients buy unapproved peptides online through telehealth sexual medicine services?
A 2025 study in Sexual Medicine found that state-level rules governing peptide availability vary dramatically, allowing patients in some states to obtain compounds that have not received FDA approval with little clinical oversight. The authors identified state regulatory inconsistency as the primary driver of this uneven access.
How does telemedicine affect access to buprenorphine for opioid use disorder?
A global scoping review published in the Journal of Telemedicine and Telecare found that telemedicine-enabled buprenorphine prescribing is practiced across many countries but faces inconsistent regulatory barriers that limit access for patients who need it. Priorities and practices differ enough between jurisdictions that patients in some regions cannot access treatment that is readily available elsewhere.
What does the American College of Physicians say about telehealth prescribing rules?
The ACP’s 2025 position paper in Annals of Internal Medicine calls for consistent federal standards governing telehealth prescribing, noting that the current patchwork of state rules creates patient safety risks. The paper argues that without federal baseline requirements, clinicians and patients face unacceptable uncertainty about what constitutes appropriate virtual prescribing.
What risks do patients face when telepharmacy has no regulatory backing?
A 2025 study in the Journal of Epidemiology and Global Health documented community pharmacists in Indonesia providing telepharmacy services without any legal or regulatory framework to govern their practice. Without oversight, there are no enforceable standards for drug counseling, error reporting, or patient data protection.
Does buprenorphine prescribed via telemedicine affect how often patients use other health services?
A retrospective cohort study published in JMIR Formative Research examined health services usage among patients receiving buprenorphine for opioid use disorder and found patterns that have implications for how telemedicine-based prescribing programs are designed and monitored. The study underscores the need for outcome tracking when controlled substances are prescribed remotely.
How can patients protect themselves when using telehealth platforms to obtain medications?
Patients should verify that any telehealth platform is staffed by licensed clinicians, confirm that the prescribing provider holds a valid license in the patient’s state, and ask specifically whether a prescribed drug is FDA-approved for the intended use. This article is not medical advice; consult a qualified healthcare professional before making any treatment decisions.
This article is for general information and is not medical, legal, or financial advice. Telehealth services, prescriptions, and insurance coverage vary by state and provider — verify a provider’s licensing and consult a qualified professional before making care decisions.